Annual Meeting Main Page | Annual Meeting Highlights | Program Purpose | Presentation Slides & Schedule
Faculty | Abstracts | Hot Topic Symposium | Hot Topic Highlights | Award Recipients
Early Career Scientists | Session Goals | Final Program | Photos | Meeting Summary
| October 2-4, 2010 Hyatt Regency Washington on Capitol Hill Washington, D.C. |
Organizers Pierre Coulie, MD, PhD ~ de Duve Institute and University of Louvain Elizabeth M. Jaffee, MD ~ Johns Hopkins University Pawel Kalinski, MD, PhD ~ University of Pittsburgh Cancer Institute Vernon K. Sondak, MD ~ H. Lee Moffitt Cancer Center |
To view slides from a presenter click on the 
icon
Led by key opinion leaders in the field, the iSBTc 25th Annual Meeting provided a scientific platform for the roughly 500 attendees to exchange cutting-edge information on basic, clinical and translational research in cancer immunotherapy.
Recipient of the Richard V. Smalley, MD Memorial Award James P. Allison, PhD (Memorial Sloan-Kettering Cancer Center) delivered a Keynote Address on checkpoint blockade in cancer therapy, presenting recent work and insights into CTLA-4 and PD-1 blockade and other immunotherapy combinations.
Keynote Speaker Cornelis J.M. Melief, MD, PhD (Leiden University Medical Center) highlighted recent advances in therapeutic vaccination against cancer induced by Human Papilloma Virus 16 (HPV-16).
Participants from 29 countries interacted over 173 posters on topics that included:
In addition to the 50 oral presentations on these topics, Howard L. Kaufman, MD (Rush University) discussed a new SITC/iSBTc initiative to create evidence-based Cancer Immunotherapy Guidelines.
Lisa Butterfield, PhD (University of Pittsburgh) reviewed activities of the SITC/iSBTc Biomarkers Taskforce, which included the recent acceptance of a collaborative manuscript from the 2009 iSBTc-FDA-NCI Workshop on Prognostic and Predictive Immunologic Biomarkers in Cancer. The NIH took the opportunity at the Annual Meeting to publically announced Martin “Mac” Cheever, MD (Fred Hutchinson Cancer Research Center, University of Washington) as the recipient of the U01 grant that will fund the Cancer Immunotherapy Trials Network (CITN), with approximately $17 million in direct and indirect costs over a 5-year period.
